Servier receives a positive CHMP opinion for ONIVYDE® in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as first line therapy in patients with metastatic pancreatic adenocarcinoma.
Improving the lives of our patients
We work tirelessly to deliver meaningful therapeutics for the patients we serve.